

# Dong Hyun Sinn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5806282/publications.pdf>

Version: 2024-02-01

236  
papers

5,765  
citations

87401

40  
h-index

145109

60  
g-index

246  
all docs

246  
docs citations

246  
times ranked

7608  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	2.4	9
2	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	1.8	48
3	Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4565-4573.	1.1	11
4	Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 69-75.	0.8	5
5	Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 380-395.	4.5	9
6	Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment. <i>PLoS ONE</i> , 2022, 17, e0262750.	1.1	1
7	Second-line Sonazoid-enhanced ultrasonography for Liver Imaging Reporting and Data System category 3 and 4 on gadoxetate-enhanced magnetic resonance imaging. <i>Ultrasonography</i> , 2022, 41, 519-529.	1.0	2
8	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	3.6	68
9	Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study. <i>BMC Medicine</i> , 2022, 20, 18.	2.3	6
10	Laparoscopic Hepatic Resection Versus Laparoscopic Radiofrequency Ablation for Subcapsular Hepatocellular Carcinomas Smaller Than 3 cm: Analysis of Treatment Outcomes Using Propensity Score Matching. <i>Korean Journal of Radiology</i> , 2022, 23, 615.	1.5	7
11	Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1215-1222.	2.8	12
12	Treatment of choice for advanced HCC with small future remnant liver volume for a hepatologist?. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2022, 26, S15-S15.	0.1	0
13	Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. <i>Scientific Reports</i> , 2022, 12, 7647.	1.6	13
14	Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2022, 151, 110328.	1.2	1
15	Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 1082-1087.	0.7	5
16	Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study. <i>Hepatology</i> , 2022, 76, 1746-1754.	3.6	24
17	Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 519-528.	1.9	14
18	Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2816-2825.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 315-324.	1.1	8
20	Incidence of and Risk Factors for Alcohol Relapse After Liver Transplantation for Alcoholic Liver Disease: Comparison Between Deceased Donor and Living Donor Liver Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 672-680.	0.9	7
21	Vanishing washout of hepatocellular carcinoma according to the presence of hepatic steatosis: diagnostic performance of CT and MRI. <i>European Radiology</i> , 2021, 31, 3315-3325.	2.3	13
22	Gadoxetic acid-enhanced MRI for differentiating hepatic sclerosing hemangioma from malignant tumor. <i>European Journal of Radiology</i> , 2021, 135, 109474.	1.2	5
23	Comparison of Super-Resolution US and Contrast Material-enhanced US in Detection of the Spoke Wheel Sign in Patients with Focal Nodular Hyperplasia. <i>Radiology</i> , 2021, 298, 82-90.	3.6	10
24	REPLY:. <i>Hepatology</i> , 2021, 73, 1622-1623.	3.6	0
25	Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablation. <i>Annals of Surgery</i> , 2021, 273, 564-571.	2.1	184
26	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	0.9	6
27	Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 274-280.	0.6	0
28	A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2021, 53, 210-215.	0.4	2
29	Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea. <i>Korean Journal of Transplantation</i> , 2021, 35, 24-32.	0.0	2
30	Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e529-e534.	0.8	14
31	Association between cancer stigma and job loss among cancer survivors. <i>Psycho-Oncology</i> , 2021, 30, 1347-1355.	1.0	19
32	Comparison of ICC patients with hepatitis B infection to those with no major risk factors for HCC. <i>Hpb</i> , 2021, 23, 945-953.	0.1	3
33	The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. <i>European Journal of Internal Medicine</i> , 2021, 89, 48-55.	1.0	26
34	The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nationwide Cohort Study. <i>Hepatology</i> , 2021, 74, 2988-2997.	3.6	10
35	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1392-1399.	1.0	13
36	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900.	1.9	15

#	ARTICLE	IF	CITATIONS
37	Evaluating mortality and recovery of extreme hyperbilirubinemia in critically ill patients by phasing the peak bilirubin level: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0255230.	1.1	7
38	Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study. <i>PLoS ONE</i> , 2021, 16, e0255624.	1.1	1
39	Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. <i>Digestive and Liver Disease</i> , 2021, 53, 1004-1010.	0.4	14
40	Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 4567.	1.7	8
41	Deep learning-based automated quantification of the hepatorenal index for evaluation of fatty liver by ultrasonography. <i>Ultrasonography</i> , 2021, 40, 565-574.	1.0	11
42	Reply to "Emergent liver transplantation for patients with acute-on-chronic liver failure". <i>Digestive and Liver Disease</i> , 2021, 53, 1361.	0.4	0
43	Initial experience with high-volume plasma exchange in patients with acute liver failure. <i>Journal of Clinical Apheresis</i> , 2021, 36, 379-389.	0.7	7
44	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00290.	1.3	9
45	Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. <i>Liver Cancer</i> , 2021, 10, 52-62.	4.2	30
46	Prevalence, risk factors, and short-term outcomes of postparacentesis acute kidney injury using revised criteria of the international club of ascites. <i>Medicine (United States)</i> , 2021, 100, e27431.	0.4	2
47	Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-8.	0.6	3
48	Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 329-335.	0.2	14
49	Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naïve hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 1328-1336.	1.9	12
50	Weight Change and Development of Subclinical Carotid Atherosclerosis Among Metabolically Healthy Adults: A Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e410-e416.	1.8	3
51	Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 2023-2032.	3.6	66
52	Deep learning with ultrasonography: automated classification of liver fibrosis using a deep convolutional neural network. <i>European Radiology</i> , 2020, 30, 1264-1273.	2.3	77
53	Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 833-839.	1.4	66
54	Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma &lt;math>\Delta</math>: emphasis on association of local tumor progression and overall survival. <i>European Radiology</i> , 2020, 30, 2391-2400.	2.3	60

#	ARTICLE	IF	CITATIONS
55	Reply. <i>Hepatology</i> , 2020, 71, 2174-2175.	3.6	0
56	RF Ablation Versus Cryoablation for Small Perivascular Hepatocellular Carcinoma: Propensity Score Analyses of Mid-Term Outcomes. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 434-444.	0.9	18
57	Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study. <i>Cancers</i> , 2020, 12, 2791.	1.7	25
58	Child-Pugh, MELD, MELD-Na, and ALBI scores: which liver function models best predicts prognosis for HCC patient with ascites?. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 951-957.	0.6	15
59	Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. <i>International Journal of Epidemiology</i> , 2020, 49, 1562-1571.	0.9	14
60	Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy. <i>JHEP Reports</i> , 2020, 2, 100175.	2.6	20
61	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1540-1550.	1.9	36
62	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	1.1	3
63	Estimation of hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2020, 73, S399.	1.8	0
64	Mean and visit-to-visit variability of glycated hemoglobin, and the risk of non-alcoholic fatty liver disease. <i>Journal of Diabetes Investigation</i> , 2020, 12, 1252-1262.	1.1	8
65	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	1.9	43
66	A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. <i>BMC Cancer</i> , 2020, 20, 504.	1.1	17
67	Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2020, 52, 881-888.	0.3	0
68	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	6.1	20
69	Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. <i>Journal of Viral Hepatitis</i> , 2020, 27, 739-746.	1.0	8
70	Use of Gadoteric Acid-enhanced Liver MRI and Mortality in More than 30,000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis. <i>Radiology</i> , 2020, 295, 114-124.	3.6	12
71	Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 896-903.	1.0	26
72	Efficacy and Safety of an mHealth App and Wearable Device in Physical Performance for Patients With Hepatocellular Carcinoma: Development and Usability Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e14435.	1.8	15

#	ARTICLE	IF	CITATIONS
73	Effect of Perfluorobutane Microbubbles on Radiofrequency Ablation for Hepatocellular Carcinoma: Suppression of Steam Popping and Its Clinical Implication. <i>Korean Journal of Radiology</i> , 2020, 21, 1077.	1.5	7
74	Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 516-528.	4.5	42
75	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 411-429.	4.5	66
76	Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 65-78.	0.7	11
77	Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection. <i>Cancer Research and Treatment</i> , 2020, 52, 1145-1152.	1.3	24
78	Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. <i>Annals of Surgical Treatment and Research</i> , 2020, 99, 238.	0.4	20
79	Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 315-317.	4.5	1
80	Comparison of Mac-2 Binding Protein Glycosylation Isomer, Fibroscan, and Other Fibrosis Markers for Assessing Liver Cirrhosis in Patients with Chronic Hepatitis B Virus-mediated Hepatocellular Carcinoma. <i>Laboratory Medicine Online</i> , 2020, 10, 109.	0.0	0
81	Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 194-204.	0.7	1
82	A Survey of Liver Cancer Specialists's™ Views on the National Liver Cancer Screening Program in Korea. <i>Journal of Liver Cancer</i> , 2020, 20, 53-59.	0.3	5
83	Comparative evaluation of QuantiFERON-TB Gold Plus for diagnosis of latent tuberculosis infection during solid organ transplantation. <i>Korean Journal of Transplantation</i> , 2020, 34, 8-14.	0.0	0
84	Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications. <i>European Radiology</i> , 2019, 29, 654-662.	2.3	38
85	The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1465-1472.	1.0	31
86	The Impact of Previous Acute Decompensation on the Long-Term Prognosis of Alcoholic Hepatitis in Cirrhotic Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1600.	1.0	2
87	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. <i>Cancers</i> , 2019, 11, 1721.	1.7	8
88	FRI-479-Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. <i>Journal of Hepatology</i> , 2019, 70, e609.	1.8	0
89	FRI-492-Long-term outcome according to initial treatment modality in multiple hepatocellular carcinoma within the Milan criteria. <i>Journal of Hepatology</i> , 2019, 70, e615.	1.8	1
90	Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. <i>Cancers</i> , 2019, 11, 1295.	1.7	11

#	ARTICLE	IF	CITATIONS
91	Nomograms in Hepatectomy Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1559-1567.	0.9	13
92	Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images. <i>Korean Journal of Radiology</i> , 2019, 20, 236.	1.5	12
93	Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. <i>BMC Cancer</i> , 2019, 19, 523.	1.1	24
94	Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2028-2035.	1.4	17
95	Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. <i>BMC Cancer</i> , 2019, 19, 286.	1.1	11
96	Radiofrequency ablation for subcardiac hepatocellular carcinoma: therapeutic outcomes and risk factors for technical failure. <i>European Radiology</i> , 2019, 29, 2706-2715.	2.3	17
97	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2019, 14, e0210730.	1.1	64
98	Long-term Prognosis of Acute-on-Chronic Liver Failure Survivors. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 134-141.	1.1	21
99	Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. <i>European Journal of Endocrinology</i> , 2019, 181, 185-192.	1.9	46
100	Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes. <i>Journal of Hepatology</i> , 2018, 69, 70-78.	1.8	106
101	Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. <i>Abdominal Radiology</i> , 2018, 43, 2309-2320.	1.0	9
102	Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1062-1071.	1.1	23
103	ABO-incompatible Living Donor Liver Transplantation With Rituximab and Total Plasma Exchange Does Not Increase Hepatocellular Carcinoma Recurrence. <i>Transplantation</i> , 2018, 102, 1695-1701.	0.5	25
104	Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. <i>Liver International</i> , 2018, 38, 1442-1448.	1.9	65
105	Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 727-733.	0.6	5
106	Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. <i>Scientific Reports</i> , 2018, 8, 4718.	1.6	68
107	Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, 1144-1152.	1.8	49
108	Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors. <i>Annals of Surgery</i> , 2018, 268, 1043-1050.	2.1	18

#	ARTICLE	IF	CITATIONS
109	Noninvasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. <i>Liver International</i> , 2018, 38, 68-75.	1.9	42
110	The qualitative and quantitative image analysis of MR imaging in patients with acute-on-chronic liver failure. <i>Clinical Imaging</i> , 2018, 47, 18-24.	0.8	1
111	Validation of prognostic scores to predict short-term mortality in patients with acute-on-chronic liver failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 900-909.	1.4	23
112	Nonalcoholic fatty liver disease and the development of reflux esophagitis: A cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1053-1058.	1.4	12
113	Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1447-1452.	0.8	13
114	Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience. <i>Annals of Surgical Treatment and Research</i> , 2018, 95, 147.	0.4	3
115	Prognosis of preoperative positron emission tomography uptake in hepatectomy patients. <i>Annals of Surgical Treatment and Research</i> , 2018, 94, 183.	0.4	8
116	Laparoscopic Donor Hepatectomy for Adult Living Donor Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2018, 24, 1545-1553.	1.3	65
117	Sarcopenia as a predictor of post-transplant tumor recurrence after living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria. <i>Scientific Reports</i> , 2018, 8, 7157.	1.6	25
118	Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	37
119	Percutaneous US/MRI Fusion-guided Radiofrequency Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma: Technical Feasibility and Therapeutic Outcomes. <i>Radiology</i> , 2018, 288, 878-886.	3.6	68
120	Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2018, 36, 25-34.	0.7	16
121	Differences in Peripheral Blood Lymphocytes between Brand-Name and Generic Tacrolimus Used in Stable Liver Transplant Recipients. <i>Medical Principles and Practice</i> , 2017, 26, 221-228.	1.1	2
122	Letter: <i>Helicobacter pylori</i> -related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 577-578.	1.9	0
123	Preoperative gadoteric acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 526-534.	1.8	299
124	Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1100-1106.	1.4	23
125	A cohort study on <i>Helicobacter pylori</i> infection associated with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2017, 52, 1201-1210.	2.3	67
126	Gadoxetic acid-enhanced magnetic resonance imaging characteristics of hepatocellular carcinoma occurring in liver transplants. <i>European Radiology</i> , 2017, 27, 3117-3127.	2.3	4



#	ARTICLE	IF	CITATIONS
127	Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. <i>Gut</i> , 2017, 66, 323-329.	6.1	125
128	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 1407-1414.	1.9	33
129	Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. <i>Journal of Hepatology</i> , 2017, 67, 1274-1280.	1.8	120
130	Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3235-3242.	1.1	44
131	Cell-surface major vault protein promotes cancer progression through harboring mesenchymal and intermediate circulating tumor cells in hepatocellular carcinomas. <i>Scientific Reports</i> , 2017, 7, 13201.	1.6	26
132	Radiofrequency ablation and transarterial chemoembolisation as first-line treatment for recurrent hepatocellular carcinoma or isolated intrahepatic recurrent hepatocellular carcinoma in transplanted livers. <i>Clinical Radiology</i> , 2017, 72, 141-149.	0.5	11
133	Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. <i>Hepatology</i> , 2017, 66, 335-343.	3.6	144
134	Tumefactive Gallbladder Sludge at US: Prevalence and Clinical Importance. <i>Radiology</i> , 2017, 283, 570-579.	3.6	18
135	Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 345-353.	1.9	54
136	Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 636-646.	0.7	17
137	Current status and strategies for viral hepatitis control in Korea. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 189-195.	4.5	21
138	Metabolically-healthy obesity is associated with higher prevalence of colorectal adenoma. <i>PLoS ONE</i> , 2017, 12, e0179480.	1.1	14
139	Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial. <i>Oncotarget</i> , 2017, 8, 52651-52664.	0.8	12
140	A case of ruptured hepatic angiomyolipoma in a young male. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 179-183.	4.5	14
141	The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 42-50.	4.5	13
142	Current status and strategies for the control of viral hepatitis A in Korea. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 196-204.	4.5	21
143	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. <i>Gut and Liver</i> , 2017, 11, 528-534.	1.4	22
144	Anti-fibrotic effect of bovine colostrum in carbon tetrachloride-induced hepatic fibrosis. <i>Precision and Future Medicine</i> , 2017, 1, 88-94.	0.5	3

#	ARTICLE	IF	CITATIONS
145	The Author's Response: Anti-Viral Therapy for Compensated Liver Cirrhosis Patients with Normal Alanine Aminotransferase. <i>Journal of Korean Medical Science</i> , 2016, 31, 825.	1.1	1
146	Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2016, 10, 939-947.	1.4	15
147	Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 47794-47807.	0.8	24
148	Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 3785.	1.4	15
149	Predicting Hepatic Steatosis in Living Liver Donors via Noninvasive Methods. <i>Medicine (United States)</i> , 2016, 95, e2718.	0.4	19
150	Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis. <i>Medicine (United States)</i> , 2016, 95, e2578.	0.4	6
151	Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: A randomized prospective study. <i>Liver Transplantation</i> , 2016, 22, 209-216.	1.3	12
152	Safety of the Use of Blood Salvage and Autotransfusion During Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2016, 264, 339-343.	2.1	57
153	Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3354-3362.	1.1	13
154	Higher Bilirubin Levels of Healthy Living Liver Donors Are Associated With Lower Posttransplant Hepatocellular Carcinoma Recurrence. <i>Transplantation</i> , 2016, 100, 1933-1938.	0.5	8
155	Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria. <i>Medicine (United States)</i> , 2016, 95, e4735.	0.4	7
156	Case-matched comparison of ABO-incompatible and ABO-compatible living donor liver transplantation. <i>British Journal of Surgery</i> , 2016, 103, 276-283.	0.1	28
157	The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?. <i>Liver International</i> , 2016, 36, 1490-1497.	1.9	51
158	Portal Vein Stenting for Portal Biliopathy with Jaundice. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 620-623.	0.9	2
159	Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. <i>Gastroenterology</i> , 2016, 151, 481-488.e1.	0.6	95
160	Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial. <i>International Journal of Hyperthermia</i> , 2016, 32, 331-338.	1.1	6
161	Characteristics and Discrepancies in Acute-on-Chronic Liver Failure: Need for a Unified Definition. <i>PLoS ONE</i> , 2016, 11, e0146745.	1.1	45
162	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. <i>PLoS ONE</i> , 2016, 11, e0165722.	1.1	33

#	ARTICLE	IF	CITATIONS
163	Cause of Mortality for Hepatocellular Carcinoma Patients who were Diagnosed within the Milan Criteria. <i>Journal of Liver Cancer</i> , 2016, 16, 101-107.	0.3	7
164	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 250-258.	4.5	42
165	Assessment of scoring systems for acute-on-chronic liver failure at predicting short-term mortality in patients with alcoholic hepatitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 9205.	1.4	17
166	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2016, 10, 295.	1.4	14
167	Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. <i>Gut and Liver</i> , 2016, 10, 796-802.	1.4	14
168	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015, 35, 2363-2369.	1.9	21
169	Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. <i>Hepatology</i> , 2015, 62, 694-701.	3.6	106
170	The Korean guideline for hepatocellular carcinoma surveillance. <i>Journal of the Korean Medical Association</i> , 2015, 58, 385.	0.1	14
171	Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. <i>Journal of Korean Medical Science</i> , 2015, 30, 1618.	1.1	12
172	Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread. <i>PLoS ONE</i> , 2015, 10, e0124434.	1.1	43
173	Early Enteral Feeding After Living Donor Liver Transplantation Prevents Infectious Complications. <i>Medicine (United States)</i> , 2015, 94, e1771.	0.4	24
174	Association between Serum Osteocalcin Levels and Non-Alcoholic Fatty Liver Disease in Women. <i>Digestion</i> , 2015, 91, 150-157.	1.2	21
175	Incidental Microscopic Bile Duct Tumor Thrombi in Hepatocellular Carcinoma after Curative Hepatectomy. <i>Medicine (United States)</i> , 2015, 94, e450.	0.4	18
176	Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3794-3800.	1.1	1
177	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. <i>Journal of Hepatology</i> , 2015, 62, 1112-1121.	1.8	50
178	Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. <i>Journal of Viral Hepatitis</i> , 2015, 22, 539-550.	1.0	18
179	Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients. <i>PLoS ONE</i> , 2015, 10, e0123554.	1.1	9
180	Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. <i>PLoS ONE</i> , 2015, 10, e0144777.	1.1	5

#	ARTICLE	IF	CITATIONS
181	Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 232.	4.5	7
182	Appropriate empirical antibiotic use and 30-d mortality in cirrhotic patients with bacteremia. <i>World Journal of Gastroenterology</i> , 2015, 21, 3587.	1.4	21
183	Serum alpha-fetoprotein may have a significant role in the surveillance of hepatocellular carcinoma in hepatitis B endemic areas. <i>Hepato-Gastroenterology</i> , 2015, 62, 327-32.	0.5	2
184	Pure red-cell aplasia and autoimmune hemolytic anemia in a patient with acute hepatitis A. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 204.	4.5	10
185	Pre-transplant Predictors for 3-Month Mortality after Living Donor Liver Transplantation. <i>The Journal of the Korean Society for Transplantation</i> , 2014, 28, 226.	0.2	1
186	Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2014, 234, 270-275.	0.4	29
187	Longitudinal change of liver stiffness by transient elastography in chronic hepatitis B patients treated with nucleos(t)ide analogue. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 195-200.	0.7	10
188	Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: A prospective, randomized trial. <i>Pancreatology</i> , 2014, 14, 263-267.	0.5	13
189	A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2014, 46, 813-817.	0.4	28
190	Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort. <i>PLoS ONE</i> , 2014, 9, e112184.	1.1	49
191	Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 151.	4.5	0
192	Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. <i>Hepatology International</i> , 2013, 7, 1010-1018.	1.9	11
193	Pre-S Mutation Is a Significant Risk Factor for Hepatocellular Carcinoma Development: A Long-Term Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2013, 58, 751-758.	1.1	25
194	Bedside index for severity in acute pancreatitis: comparison with other scoring systems in predicting severity and organ failure. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2013, 12, 645-650.	0.6	76
195	Blood lead is significantly associated with metabolic syndrome in Korean adults: an analysis based on the Korea National Health and Nutrition Examination Survey (KNHANES), 2008. <i>Cardiovascular Diabetology</i> , 2013, 12, 9.	2.7	70
196	Steatosis Among Living Liver Donors Without Evidence of Fatty Liver on Ultrasonography. <i>Transplantation</i> , 2013, 95, 1404-1409.	0.5	24
197	Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 173.	4.5	9
198	Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels. <i>World Journal of Gastroenterology</i> , 2013, 19, 2256.	1.4	3

#	ARTICLE	IF	CITATIONS
199	Screening for extrahepatic metastases by additional staging modalities is required for hepatocellular carcinoma patients beyond modified UICC stage T1. <i>Hepato-Gastroenterology</i> , 2013, 60, 328-32.	0.5	3
200	Ultrasonographically Detected Non-Alcoholic Fatty Liver Disease Is an Independent Predictor for Identifying Patients With Insulin Resistance in Non-Obese, Non-Diabetic Middle-Aged Asian Adults. <i>American Journal of Gastroenterology</i> , 2012, 107, 561-567.	0.2	104
201	Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine resistance. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1454-1460.	1.4	5
202	Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease. <i>Liver International</i> , 2012, 32, 937-944.	1.9	29
203	Impact of previous gastric or colonic resection on polyethylene glycol bowel preparation for colonoscopy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 1554-1559.	1.3	28
204	Factors associated with adherence to the recommended postpolypectomy surveillance interval. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 1690-1695.	1.3	15
205	Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 306-312.	1.4	37
206	Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. <i>World Journal of Gastroenterology</i> , 2012, 18, 6996.	1.4	26
207	The Clinical and Laboratory Characteristics of Patients with Chronic Hepatitis B Using Current or Past Antiviral Therapy in Korea: A Multi-Center, Nation-Wide, Cross-Sectional Epidemiologic Study. <i>Gut and Liver</i> , 2012, 6, 241-248.	1.4	7
208	Hepatogastroenterology. <i>Hepato-Gastroenterology</i> , 2012, 59, 1-6.	0.5	3
209	Screening for Extrahepatic Metastases by Additional Staging Modalities is Required for Hepatocellular Carcinoma Patients Beyond Modified UICC Stage T1. <i>Hepato-Gastroenterology</i> , 2012, . .	0.5	2
210	Pathological bolus exposure may define gastro-esophageal reflux better than pathological acid exposure in patients with globus. <i>Hepato-Gastroenterology</i> , 2012, 59, 317-20.	0.5	2
211	Mortality after surgery in patients with liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 51-59.	0.8	58
212	Efficacy of peginterferon-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 469-476.	1.4	21
213	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian Patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, no-no.	1.4	34
214	Increasing Incidence of Inflammatory Bowel Disease Among Young Men in Korea Between 2003 and 2008. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1154-1159.	1.1	42
215	Defining Virologic Relapse in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2432-2438.	1.1	4
216	Virological response to adefovir monotherapy and the risk of adefovir resistance. <i>World Journal of Gastroenterology</i> , 2011, 17, 3526.	1.4	6

#	ARTICLE	IF	CITATIONS
217	Formal documentation of withdrawal time improves the quality of colonoscopic observation. <i>Hepato-Gastroenterology</i> , 2011, 58, 779-84.	0.5	3
218	Clinical usefulness of glycosylated hemoglobin as a predictor of adenomatous polyps in the colorectum of middle-aged males. <i>Cancer Causes and Control</i> , 2010, 21, 939-944.	0.8	17
219	Are the Echogenicities on Intraductal Ultrasonography Really Biliary Microlithiasis?. <i>Digestive Diseases and Sciences</i> , 2010, 55, 836-841.	1.1	6
220	Adenoma incidence after resection of sporadic colorectal cancer with microsatellite instability. <i>Journal of Surgical Oncology</i> , 2010, 101, 577-581.	0.8	5
221	Change in cross-sectional area of esophageal muscle does not correlate with the outcome of achalasia after pneumatic balloon dilatation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 539-543.	1.4	7
222	Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 957-963.	1.4	7
223	Regional differences of the effects of acetylcholine in the human gastric circular muscle. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G1198-G1203.	1.6	16
224	Efficacy and Tolerability of Split-Dose Magnesium Citrate: Low-Volume (2 Liters) Polyethylene Glycol vs. Single- or Split-Dose Polyethylene Glycol Bowel Preparation for Morning Colonoscopy. <i>American Journal of Gastroenterology</i> , 2010, 105, 1319-1326.	0.2	89
225	The Speed of Eating and Functional Dyspepsia in Young Women. <i>Gut and Liver</i> , 2010, 4, 173-178.	1.4	20
226	Vaccination Rate and Seroepidemiology of Hepatitis A in Chronic-Hepatitis-B-Infected Individuals in the Korean Army. <i>Gut and Liver</i> , 2010, 4, 207-211.	1.4	2
227	Methylation and API2/MALT1 fusion in colorectal extranodal marginal zone lymphoma. <i>Modern Pathology</i> , 2009, 22, 314-320.	2.9	10
228	Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1504-1509.	1.4	40
229	Effectiveness of each Bethesda marker in defining microsatellite instability when screening for Lynch syndrome. <i>Hepato-Gastroenterology</i> , 2009, 56, 672-6.	0.5	2
230	Therapeutic Effect of <i>Lactobacillus acidophilus</i> -SDC 2012, 2013 in Patients with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2714-2718.	1.1	152
231	Disease progression and the risk factor analysis for chronic hepatitis C. <i>Liver International</i> , 2008, 28, 1363-1369.	1.9	35
232	Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1275-1281.	1.9	44
233	Documentation of Withdrawal Time Improves Adenoma Detection During Colonoscopy. <i>Gastrointestinal Endoscopy</i> , 2008, 67, AB297.	0.5	0
234	Effect of Balloon-Occluded Retrograde Transvenous Obliteration on the Natural History of Coexisting Esophageal Varices. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 974-979.	1.1	60

#	ARTICLE	IF	CITATIONS
235	Development of Barrett's Esophagus Soon after Total Gastrectomy. Gut and Liver, 2008, 2, 51-53.	1.4	4
236	Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. Scandinavian Journal of Gastroenterology, 0, , 1-8.	0.6	0